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SUMMARY
We performed a single-blind, randomized phase 1 trial of
the long synthetic peptide (LSP) of merozoite surface pro-
tein-3 (MSP3) in adults living in Burkina Faso. Thirty
eligible volunteers were randomized to receive either the
MSP3-LSP candidate vaccine or tetanus toxoid vaccine as
a control. A dose of each vaccine was administered on days
0, 28 and 112 and the vaccine was formulated with alumin-
ium hydroxide. Humoral immune responses were assessed by
ELISA at days 0, 28, 56, 112, 140, 252 and 365 and cell-
mediated immune responses by lymphoproliferation assay
and by ELISA on days 0, 56 and 140. IgG responses to four
peptides of MSP3 were similar in both vaccine groups.
Higher IgG concentrations were recorded after the beginning
of malaria high transmission season in both vaccine groups.
The lymphocyte proliferation and the production of IFN-c in
response to stimulation with the four overlapping peptides
increased following vaccination in the MSP3-LSP vaccine
group, but did not change appreciably in the control group.
In contrast to natural infection, MSP3-LSP did not boost
humoral responses to the four overlapping peptides of MSP3
to any detectable degree in our semi-immune adult. MSP3-
LSP may be more immunogenic in young children with little
or no acquired immunity.
Keywords adults, immunogenicity, merozoite surface protein-
3, phase 1b
INTRODUCTION
An effective antimalarial vaccine remains a highly desir-
able goal. Several Plasmodium falciparum antigens identi-
fied as vaccine candidates have been sequenced and
immunologically characterized. Among these antigens,
merozoite surface protein-3 (MSP3) of the asexual stage
has emerged as a promising candidate (1–3). In contrast
to the N-terminus, the C-terminal part of the molecule, is
highly conserved among field isolates of the parasite (4,5).
Many seroepidemiological and laboratory studies con-
ducted with samples from different settings have reported
that cytophilic antibodies to MSP3 (IgG1 and IgG3) pre-
dominate in protected individuals while unprotected indi-
viduals produce mostly noncytophilic antibodies (IgG2
and Ig4) (1,2). Three peptides (b, c and d) from the C-ter-
minal region of MSP3 were used to affinity purify
antibodies that possessed antibody-dependant cellular
inhibition activity from sera from a population in which
malaria is endemic (6). The transfer of human monocytes
together with antibodies to MSP3 induced rapid clearance
of parasites in an immunocompromised mouse model of
P. falciparum (7). In Saimiri sciureus and Aotus nancymai,
recommended as primate models for malaria research by
WHO, MSP3 can induce protective immunity against
experimental P. falciparum infection (7–10). Two human
phase 1 MSP3 vaccine trials have been conducted in
malaria-nave and in semi-immune adults (11,12). In
malaria-nave, Swiss adults MSP3 long synthetic peptide
(MSP3-LSP) was reported to be safe and to induce a
marked specific anti-MSP3-LSP antibody response, an
anti-native MSP3 antibody response, a T-cell antigen-
specific proliferative response and gamma interferon
production (11). In semi-immune males aged 18–40 years,
living in a malaria-endemic area MSP3-LSP was reported
to be safe and immunogenic (12).
In this paper, we present in more detail the immunologi-
cal responses (IgG antibodies, lymphocyte proliferation
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and gamma interferon production) to four overlapping
peptides of MSP3 of the semi-immune participants in the
latter trial in Burkina Faso. The four overlapping small
peptides MSP3-a, MSP3-b, MSP3-c and MSP3-d, which
span the MSP3-LSP sequence, each define a B-cell epitope
and a T-cell epitope (6,11). Antibody responses to peptides
b, c and d have been associated with protection in the past
(6,13).
MATERIALS AND METHODS
Study site
The study site is described elsewhere (12). Briefly, the
study was conducted at the Medical Centre, Sector 30,
Ouagadougou in Burkina Faso. Malaria transmission is
seasonal, being low during the dry season (November to
May) and high during the rainy season from June to Octo-
ber. During the rainy season, the estimated incidence of
clinical malaria in children under 5 years of age is one epi-
sode per child with P. falciparum accounting for more than
95% of infections.
Study participants
Thirty male volunteers, aged 18–40 years living in the
village of Balonghin, a village 50 km south of Ouagadou-
gou, were recruited under a protocol approved by the ethi-
cal committee for medical research of the Ministry of
Health, Burkina Faso and by the Ethics Committee of the
London School of Hygiene and Tropical Medicine. The
trial was conducted in compliance with the International
Conference on Harmonization’s Good Clinical Practice
principles, the Declaration of Helsinki and the regulatory
requirements of Burkina Faso. Individual written informed
consent was obtained from all participants. Individuals
were eligible for inclusion in the trial if they were found to
be healthy at a general medical examination, indicated
their intention to reside in the village for the duration of
the trial (12 months) and gave written informed consent.
Exclusion criteria included: (i) symptoms of any condition
that could interfere with the interpretation of the trial
results or compromise the health of the subject; (ii) any
clinically significant, abnormal haematological parameters;
(iii) seropositivity to HIV, HBV or HCV; (iv) Schistosoma
haematobium infection; (v) history of immunosuppressive
therapy (steroids, immunomodulator or immunosuppres-
sor) within the 3 months preceding enrolment; (vi) sus-
pected or known hypersensitivity to any of the vaccine
components or to a previously administered vaccine and
(vii) history of complete anti-tetanus vaccination. Each
participant was assigned a unique identification number
and given an identity card to assist correct identification
subsequently.
Study design
The study was designed as a single-blind, randomized trial
to assess the safety and the immunogenicity of three doses
of 30 lg of MSP3-LSP adsorbed on aluminium hydroxide
(12). Thirty eligible volunteers (15 per arm) were random-
ized to receive either the MSP3-LSP candidate vaccine or
tetanus toxoid (TT) vaccine as a control. A dose of each
vaccine was administered on days 0, 28 and 112. The vol-
unteers were transported from Balonghin to the Medical
Centre for vaccination and for planned follow-up visits.
The laboratory staff who performed the immunological
assays were not aware which study participants had been
allocated to each arm.
Vaccines
The MSP3-LSP vaccine is an LSP containing the amino-
acid sequence 186–276 of the P. falciparum MSP-3. The
vaccine was manufactured by Dictagene (Epalinges,
Switzerland) undergoodmanufacturing practices conditions,
produced in lyophilized form and delivered in multidose
vials; excipients were sodium chloride 9 mg ⁄mL, trisodium-
citrate 10 mM (2Æ94 mg ⁄mL), disodium-phosphate buffer
10 mM (1Æ42 mg ⁄mL). Before administration, the vaccine
was reconstituted using 1 mL of isotonic saline solution
(9&) and mixed with 1 mL of aluminium hydroxide, under
sterile conditions (under a laminar hood), following the pro-
cedure recommended by the manufacturer. A minimum
interval of 60 min was allowed between reconstitution and
administration of the vaccine to allow adequate adsorption
of the vaccine. The adsorbed vaccine was aliquoted into sin-
gle-use syringes (BioCare Nordic ApS, Roskilde, Denmark).
From each multidose vial, three individual vaccine doses of
0Æ5 mL, containing 30 lg of peptide, were prepared.
The TT vaccine used was produced from a formalde-
hyde detoxified and purified tetanus toxin provided by the
Statens Serum Institute, Copenhagen, Denmark (batch no.
7906). The vaccine was reconstituted using the same adju-
vant as the MSP3-LSP vaccine (aluminium hydroxide and
buffer solution).
Determination of immunological parameters
Blood sampling
Blood for the analysis of both humoral and cellular
immune responses was obtained before each immunization
and at specific time points during the study.
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Humoral immune responses on days 0, 28, 56, 112, 140,
252 and 365 were evaluated using whole blood samples
collected on heparin as an anticoagulant (VF-109SHL,
Terumo Europe n.v, Leuven, Belgium). Lymphocyte prolif-
eration and cytokine production were only measured on
days 0, 56 (28 days after the second injection at day 28)
and 140 (28 days after the last injection at day 112).
The first blood draw for immunological assays (on day
0) was done in October 2003 (1 month before the end of
malaria high transmission period) and the last (day 252)
was done at the end of June 2004, shortly after the begin-
ning of the rainy season at a time when malaria transmis-
sion was beginning to increase after the low levels of the
dry season.
MSP3-LSP and MSP3 overlapping peptides
We studied immunological responses using the following
MSP3 peptides:
1. The vaccine peptide MSP3-LSP: this corresponds to
a fully conserved region covering amino acids 181–276
(product number 00FS021#1B, Dictagene) (sequence
RKTKEYAEKAKNAYEKAKNAYQKANQAVLK AK
EASSYDYILGWEFGGGVPEHKKEENMLSHLYVSSK
DKENISKENDDVLDEKEEEAEETEEEELE) of the
C-terminal region of MSP3 (386 amino acids long) from
the P. falciparum strain Fc27 (4).
2. Four overlapping peptides (a, b, c and d) which span
86% of MSP3-LSP: MSP3-a amino acids 194–217 (Prod-
uct number Dicta-F64#1C, Dictagene) (HERAKNAY
QKANQAVLKAKEASSY); MSP3-b amnino acids 211–
237 (Product number Dicta-G40#1C, Dictagene) (AKE-
ASSYDYILGWEFGGGVPEHKKEEN); MSP3-c amino
acids 230–257 (Product number Dicta-G65#1C, Dictagene
SA) (PEHKKEENMLSHLYVSSKDKENISKENE) and
MSP3-d amino acids 238–276 (Product number Dicta-
G41#1C, Dictagene) (MLSHLYVSSKDKENISKENDD-
VLDEKEEEAEETEEEELE).
These peptides were synthesized, purified, bottled and
lyophilized following GMP procedures (batch no.
00FS023, RMF Dictagene).
Tetanus toxoid (ATP PTC 10005 PREP No 2, Pasteur
Merieux, Marcy L’Etoile, France) and phytohemagglutinin
(PHA) (PHA-L, cat# L2769; Sigma) were used as controls.
Assessment of antibody responses
Merozoite surface protein-3 long synthetic peptide-specific
IgG concentrations were measured by ELISA. Concentra-
tions of IgG specific to the four overlapping peptides of
MSP3 (a, b, c and d) were also measured. The ELISA was
done according to the Afro Immuno Assay standard oper-
ating procedure (SOP number AIA-007-03) (3,12). In
brief, microtitre plates (NUNC – Maxisorp F 96 439454,
Roskilde, Denmark) were coated with the appropriate syn-
thetic peptide (1 lg ⁄mL), incubated overnight at 4C, and
blocked with 3% milk powder (cat# 92964, Marvel,
Dublin, Ireland) in PBS-Tween 20 for 1 h. Plasma samples
diluted 1 : 200 were added in duplicate and incubated at
room temperature for 2 h. Plates were washed four times
between each step. Plates were developed with either per-
oxidase conjugated goat anti-human IgG (secondary anti-
body) (Caltag – H10007, Carlsbad, California, USA). The
revealing was done with peroxidase conjugated goat anti-
mouse IgG.
Bound secondary antibody for IgG were quantified by
colouring with ready to use TMB (3,3¢,5,5¢-tetramethyl-
benzidine) substrate (cat# 4390A; Kem-En-Tec diagnos-
tics, Taastrup, Denmark). Optical density (OD) was read
at 450 nm with a reference at 620 nm, and the OD value
of the test-sample were converted into arbitrary units by
means of a standard curve on each plate.
For antibody quantification, to control for interassay
and day-to-day variations in the standardized ELISA pro-
cedure, threefold serial dilutions of reference standard
reagents (IgG) were directly coated on each ELISA plate
at a starting concentration of 1000 ng ⁄mL (100 lL ⁄well).
Optical density values for the test samples were converted
into antibody units with the standard reference curves gen-
erated for each ELISA plate using a four-parameter curve-
fit MICROSOFT EXCEL-based application. Samples were
re-tested if the coefficient of variation between duplicate
absorbance values were higher than 15% and plates were
also re-tested if the R-square value of the standard curve
was less than 97%.
However if the OD at 1 : 200 was above the readable
range of the ELISA plate reader, the test sample was
further diluted.
The positive control plasmas were from positive Liberian
plasma samples and the negative controls from Danish
plasma samples graciously provided by Michael Theisen
from Statens Serum Institute (Copenhagen, Denmark).
Plates not meeting pre-defined limits for control values
were excluded and the samples re-tested.
Assessment of cellular immune responses
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinized venous whole blood by gradient centri-
fugation on Ficoll-Hypaque (Histopaque 1077; Sigma
1077-1). For the proliferative assays, PBMC were washed
and adjusted to a concentration of 2 · 106 cells ⁄mL in
Dulbecco’s MEM supplemented with HEPES buffer, 100-
U ⁄mL penicillin ⁄ streptomycin, nonessential amino acids
and heat-inactivated human AB serum. Fresh PBMC were
distributed in sextuplicates in 96-well flat-bottom plates
(2 · 105 cells ⁄well) (Costar cat# 3596; Corning
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Incorporated, New York, USA). Peripheral blood mono-
nuclear cells were stimulated with a range of concentra-
tions of MSP3-a, MSP3-b, MSP3-c and MSP3-d peptides
(2 and 10 lg ⁄mL), with TT (10 lg ⁄mL) and PHA
(10 lg ⁄mL) as positive controls and incubated at 37C in
5% CO2 ⁄ 95% air. Peripheral blood mononuclear cells
from each volunteer were incubated in the same condi-
tions in media alone to serve as negative control. After
6 days, 100-lL supernatant was removed and replaced
with proliferation medium containing [3H]-thymidine
(1 lCi ⁄well). The cells were harvested 24 h later onto
glass fibre filters and [3H]-thymidine incorporation was
measured by liquid scintillation (Wallac scintillation prod-
ucts, Milton Keynes, UK) in a b-counter. The stimulation
index (SI) was defined as the mean count per minute of
experimental wells divided by the mean of negative
control wells (cells and medium alone).
Production of IFN-c in supernatants of PBMC pre-
pared and plated as described for proliferation assay,
and stimulated with 10 lg ⁄mL for MSP3 fragments or
controls, was measured by ELISA (Elipair, Diaclone,
BesanÅon, France), following the manufacturer’s instruc-
tions.
Data analysis
The database was created in MICROSOFT EXCEL. Descriptive
analysis of the data were undertaken using STATA (version
8Æ2; College Station, TX, USA). Given the small sample
size, formal statistical analysis were not used to compare
vaccine groups. Median concentrations of IgG, SI and
IFN-c concentration and 95% confidence interval were
calculated by using log10-transformed values.
RESULTS
Humoral responses to MSP3-LSP and to four
overlapping peptides
To identify immunogenic regions, IgG responses to four
overlapping peptides MSP3-a, MSP3-b, MSP3-c and
MSP3-d were examined. No major differences in responses
between the two vaccine groups were observed (Figure 1).
Higher IgG concentrations against the peptides were
recorded after day 140 at the beginning (day 252) and
peak of malaria high transmission season (day 365) in
both vaccine groups. The highest antibody responses were
generally to MSP3-c.
Cell-mediated immunity to MPS3-LSP and to four
overlapping peptides
Lymphocyte proliferation in response to MSP3 fragments
is shown in Figure 2. Two different concentrations (10 and
2 lg ⁄mL) of the four overlapping peptides were used to
stimulate the PBMC (data for 2 lg ⁄mL are not shown).
The stimulation was higher with the 10 lg ⁄mL. The SIs
were similar in both vaccine groups at day 0 but increased
in MSP3-LSP vaccine group post-vaccination (days 56
and 140) for all fragments, with the strongest response
being to peptide MSP3-a (Figure 2). At the higher concen-
tration of 10 lg ⁄mL at day 56 73% (11 ⁄ 15), 73% (11 ⁄ 15),
53% (8 ⁄ 15) and 40% (6 ⁄ 15) of volunteers of MSP3-LSP
vaccine group had SI at least the double of those observed
at D0, respectively, for MSP3-a, MSP3-b, MSP3-c and
MSP3-d. Between 0 and 27% of volunteers had similar
responses in the control group.
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IFN-c was measured in PBMC supernatants following
stimulation with the four MSP3 overlapping peptides at
10 lg ⁄mL before the first vaccination and after the second
and the third vaccinations (Figure 3). In the MSP3-LSP
group, IFN-c levels following stimulation with MSP3 frag-
ments remained relatively stable over time while in the
control arm IFN-c levels declined substantially.
DISCUSSION
The aim of this paper was to investigate the pattern of
humoral and cell-mediated immunity to the four overlap-
ping peptides of the highly conserved C-terminal part of
MSP3 in semi-immune adults from 20 to 45 years immu-
nized with MSP3-LSP, a malaria vaccine candidate. Previ-
ous experience has shown that LSP were safe and
immunogenic (14–19). Despite the small sample size, the
results presented in this paper suggest that, in contrast to
natural infection, MSP3-LSP vaccine adsorbed on alumin-
ium hydroxide did not boost humoral responses to the
four overlapping peptides of MSP3. The vaccine may,
however, have boosted some components of cell-mediated
immunity.
The findings with respect to humoral responses against
the short peptides are similar to the those for IgG
responses against MSP3-LSP obtained with the same vol-
unteers (12) and are in contrast to the results of the phase
1 trial conducted in nave Swiss adults who displayed
strong, specific anti-MSP3-LSP antibody responses (11).
IgG antibody concentrations to MSP3-LSP (12) and to
MSP3 fragments in naturally exposed adults were already
high at baseline, presumably as a result of exposure to
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natural infection and the vaccine did not appear to have
any boosting effect. Previous trials conducted in Kenya
and Papua New Guinea have reported similar findings
(20,21). The authors observed no significant difference in
antibody titres against some peptides between the controls
and the vaccines groups. The most likely explanation is that
the high intensity transmission may have overshadowed the
inductive capacity of the vaccine. Antibody concentrations
measured at the two time points after day 140, in June and
October during the high transmission period, suggest a
modest boosting effect of exposure to natural infection.
The magnitude of IgG responses to these peptides was
highest for IgG against MSP3-c, whose antiparasitic effect
has been already demonstrated (6). However, we have not
been able to show that antibody patterns to each region
differ markedly in terms of levels in contrast to the previ-
ous data from Senegal where the higher concentrations
have been reported for MSP3-b, MSP3-c and MSP3-d (6).
This difference may be due to the malaria transmission
level which is higher in our setting compared with Dielmo
(Senegal), to the population genetic backgrounds and to
our small sample size.
Cell-mediated immunity was investigated by measuring
proliferative responses and IFN-c measured by ELISA in
proliferation culture supernatant. The SI for MSP3-LSP
(12) and the four overlapping peptides measured before the
first injection in October (day 0), just at the end of the peak
of malaria high transmission period, was low and similar in
both vaccine groups. The low SI may be due to the high
background at this period of malaria transmission and this
may be explained by the high antigenic pressure to which
the study volunteers were exposed at the time of blood sam-
pling. The T-cell response in individuals exposed to high
antigenic pressure is uncertain when assessing the immune
responses in vitro. During the high transmission season, the
permanent exposure of the immune system to plasmodial
antigens might induce increased levels of lymphocyte acti-
vation and hide the in vitro activity. This phenomenon was
observed with high mean counts per minute of the negative
control (data not shown). Proliferative responses and IFN-c
secretion in response to stimulation with MSP3-LSP (12)
and the overlapping peptides were boosted following vacci-
nation with MSP3-LSP. This immunogenicity is likely
related to the four T-cell epitopes previously identified in
malaria endemic area (6). The geometric means of the SI
and the proportion of volunteers with high SI as well as the
concentrations of IFN-c in the supernatants were high in
MSP3-LSP vaccinated volunteers compared with baseline
(D0) and to the control group. Merozoite surface protein-3
long synthetic peptide appears to stimulate cell-mediated
immunity even in these semi-immune volunteers with some
pre-existing immunity as the result of many years of natural
exposure. This finding is accordance with the phase 1a trial
in nave volunteers where MSP3-LSP proved able to trigger
in humans a very high prevalence of strong T-cell responses,
as shown by the high proliferation indices and IFN-c
production (11).
T-cell responses to the four peptides spanning the C-ter-
minal part of MSP3 were generally lower than the
responses to the full MSP3-LSP measured in parallel (12).
The results indicate that these peptides have also been able
to boost T-cell responses in MSP3-LSP vaccine group
showing that the T-cell immunogenicity is likely related to
these four T-cell epitopes previously identified in humans
living in malaria endemic area (6). It also indicates that
each of these four peptides tested defined at least one
T-cell epitope and IFN-c production results suggest that
at least the responding cells belonged to the Th1-like type.
CONCLUSION
Our data suggest that humoral responses to the MSP3 pep-
tides were not boosted in semi-immune adults immunized
with the full MSP3-LSP, perhaps because of high baseline
antibody levels. However, there is some indication that the
vaccine was able to illicit cellular immune responses in these
semi-immune volunteers. Merozoite surface protein-3 long
synthetic peptide is immunogenic in nave adult volunteers
and may therefore be more immunogenic in young children
in endemic areas who have had less time to develop
acquired immunity that the adults reported on here.
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